US 8288342
Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
granted A61KA61K31/21A61K31/56
Quick answer
US patent 8288342 (Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate) held by TEVA WOMEN'S HEALTH, INC. expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Grant date
- Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/21, A61K31/56, A61P, A61P35/00